Title: AB118. Validation of next generation sequencing by Sanger sequencing
Abstract: Background and objective
Development of the next generation sequencing (NGS) platform was driven by the completion of the Human Genome Project in 2003. With the availability of NGS, the time taken for sequencing of humongous genomic regions was greatly reduced and data generated per unit DNA was also significantly increased. Though the cost to use NGS in a clinically setting is far from ideal, economically speaking, there is a significant decrease in the average cost per sequenced base. To validate findings of NGS on mutation detected for FBN1, TGFBR2, RAF1, RTEL1, LMNA, MID2, KCNK9, DMD, SMARCA2 and IQSEC2 by using gold standard, Sanger Sequencing.
Publication Year: 2015
Publication Date: 2015-05-09
Language: en
Type: article
Access and Citation
Cited By Count: 1
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot